NCT00748709 2025-02-11Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification.Boehringer IngelheimPhase 2 Terminated20 enrolled 11 charts
NCT01320280 2022-07-01BIBW 2992 (Afatinib) for the Treatment of Patients With HER2-positive, Hormone-refractory Prostate CancerUniversitätsklinikum Hamburg-EppendorfPhase 2 Terminated29 enrolled